Immunovant (IMVT) investor relations material

Executive summary

• Reported positive phase 2 results for brepocitinib in cutaneous sarcoidosis, with 100% of high-dose patients achieving clinically meaningful improvement and strong safety profile.

• IMVT-1402 registrational trial in difficult-to-treat rheumatoid arthritis fully enrolled; topline data expected in H2 2026.

• Multiple pipeline updates: NDA for brepocitinib in dermatomyositis submitted, phase 2B studies for IMVT-1402 in D2T-RA and mosliciguat in PH-ILD fully enrolled.

• No product revenue to date; all activities are pre-commercial and centered on clinical development and regulatory progress.

• $550 million raised in underwritten financing, extending cash runway to potential IMVT-1402 launch in Graves' disease.

Financial highlights

• R&D expense for the quarter was $165M (GAAP), $147M (non-GAAP); G&A was $175M (GAAP), $71M (non-GAAP).

• Net loss for Q3 FY2026 was $110.6M ($0.61 per share); non-GAAP net loss was $97.5M.

• Cash and cash equivalents totaled $994.5M as of December 31, 2025, up from $714.0M at March 31, 2025, mainly due to a $550M equity raise.

• Consolidated cash position remains strong at $4.5B, providing ample runway to profitability and flexibility for further investments.

• Net loss for the nine months ended December 31, 2025 was $357.8M, up from $307.4M year-over-year.

Outlook and guidance

• Pivotal phase 3 readout for brepocitinib in NIU expected in H2 2026; phase 3 in cutaneous sarcoidosis to start this year.

• Topline data for IMVT-1402 in D2T RA and CLE expected in H2 2026; Graves' disease and MG data expected in 2027.

• Existing cash is expected to fund operating expenses and capital requirements for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease.

• Multiple NDA and BLA filings anticipated, with several commercial launches possible in the next few years.

• Anticipates continued net losses and significant R&D spending for the foreseeable future.